OT10 Stock Overview Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Orchard Therapeutics plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Orchard Therapeutics Historical stock prices Current Share Price US$14.60 52 Week High US$15.60 52 Week Low US$4.02 Beta 0.55 1 Month Change -0.68% 3 Month Change -0.68% 1 Year Change 137.40% 3 Year Change -69.33% 5 Year Change n/a Change since IPO -88.16%
Recent News & Updates
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel) Mar 20
Orchard Therapeutics Files Form 15 Feb 06
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome Feb 05
Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others. Jan 26 Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index
New major risk - Financial position Dec 17 See more updates
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel) Mar 20
Orchard Therapeutics Files Form 15 Feb 06
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome Feb 05
Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others. Jan 26 Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index
New major risk - Financial position Dec 17
Insufficient new directors Dec 15
Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy Dec 12
Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH Dec 01
Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023 Nov 17
Third quarter 2023 earnings released: US$1.55 loss per share (vs US$3.71 loss in 3Q 2022) Nov 14
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023 Oct 27 Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million. Oct 06
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review Sep 20
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023 Sep 01
New major risk - Shareholder dilution Aug 10
Insufficient new directors Aug 09
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT May 20
Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations Jan 18
Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH Jan 06
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA Dec 13
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel) Dec 02
Insufficient new directors Nov 21
Insufficient new directors Sep 14
Insufficient new directors Jun 09
Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq Apr 09
Insufficient new directors Feb 22
Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones Jan 12
Insufficient new directors Jan 04
Insufficient new directors Nov 16
Insufficient new directors Oct 07
Insufficient new directors Sep 21
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event Sep 15
Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V. Jul 02
Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs Jun 30
Independent Non-Executive Director Jon Ellis has left the company Jun 22
Orchard Therapeutics Announces Data Published in the New England Journal of Medicine Evaluating the Safety and Efficacy of Investigational Gene Therapy Products, Including OTL-101 May 12 Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
Revenue misses expectations Mar 04
Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019) Mar 04
Orchard Therapeutics plc Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome Feb 10
Orchard Therapeutics plc announced that it expects to receive $149.999996 million in funding from RA Capital Management, L.P., Avidity Partners Management LP, Casdin Capital, LLC, Farallon Capital Management, L.L.C., Citadel Enterprise Americas LLC and other investors Feb 06
New 90-day high: €6.30 Feb 06
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer Jan 31
Orchard Therapeutics Secures Partnerships to Broaden Access to Libmeldy for Eligible Patients in Middle East & Turkey Jan 20
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD) Jan 15
New 90-day high: €5.15 Jan 06
Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy Dec 23
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Dec 10
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD) Nov 20
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Nov 13
Orchard Therapeutics Announces Presentation of New Clinical Data At the Upcoming 62nd American Society of Hematology Annual Meeting Nov 06
Revenue beats expectations Nov 05
Orchard Therapeutics plc Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) Oct 17
Orchard Therapeutics Receives EMA Prime Designation for OTL-203 for the Treatment of MPS-I Oct 05
New 90-day low: €3.24 Oct 02 Shareholder Returns OT10 DE Biotechs DE Market 7D 0% 5.5% 1.2% 1Y 137.4% -3.7% 10.1%
See full shareholder returns
Return vs Market: OT10 exceeded the German Market which returned -0.9% over the past year.
Price Volatility Is OT10's price volatile compared to industry and market? OT10 volatility OT10 Average Weekly Movement n/a Biotechs Industry Average Movement 7.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: OT10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OT10's volatility change over the past year.
About the Company Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.
Show more Orchard Therapeutics plc Fundamentals Summary How do Orchard Therapeutics's earnings and revenue compare to its market cap? OT10 fundamental statistics Market cap €348.84m Earnings (TTM ) -€66.92m Revenue (TTM ) €20.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) OT10 income statement (TTM ) Revenue US$21.84m Cost of Revenue US$79.52m Gross Profit -US$57.68m Other Expenses US$15.24m Earnings -US$72.92m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -3.20 Gross Margin -264.11% Net Profit Margin -333.90% Debt/Equity Ratio 31.9%
How did OT10 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/01/24 18:57 End of Day Share Price 2024/01/24 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Orchard Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Charles Duncan Cantor Fitzgerald & Co. Emma Nealon Cantor Fitzgerald & Co. Graig Suvannavejh Goldman Sachs
Show 7 more analysts 
